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From Pregnancy Loss to COVID 




Large scientific evidence achieved during the second half of the past century points 
to a leading role of inflammation in the pathogenic mechanism of the main pregnancy 
complications, such as abortion, pregnancy loss, premature delivery, infection, fetal 
encephalopathy, enterocolitis, pulmonary hyaline membrane diseases and death. 
Thinking about pregnancy inflammation, one must refer today to the umbalance of 
the normal mediators of organic functions: cytokins, peptides, nucleosides, pros-
tanoids. Indeed, according to the order and quantity of their release, they are involved 
either in physiology or in pathology of pregnancy. At this regard, it has been shown 
that Th1-type immunity is incompatible with successful pregnancy. Regulation of the 
mediators of maternal functions is largely under fetal genetic control. Assessment of 
the fetal role derives from studies showing an umbalance of cytokines and plasmino-
gen activator system, an increase of endothelin, a downregulation of adenosine recep-
tors, in the fetal compartment, in aneuploid pregnancies. The resulting functional 
deviations deal with inflammation, imfection, coagulation, impaired utero-placental 
perfusion, possibly leading to fetal demise and ominus maternal complications. SARS-
COV-2 infection, on the other hand, is characterized by a similar umbalance of the 
inflammatory mediators, leading to hyperactivation of a type-1 lymphobyte T-helper 
response, which ends in a possibly fatal cytokine storm syndrome. While SARS-COV-2 
infection recognizes a viral etiology, the cause of pregnancy inflammation must be 
recognized in the inability of the fetus to control the maternal immune response. 
Therefore, the preventive measures are quite different, although both benefit of a 
similar anti-inflammatory, antibiotic and anti-coagulant therapy.
Keywords: pregnancy inflammation, abortion, FIRS, SARS-COV-2, IL-6, viral 
pneumonia, cytokine storm
1. Introduction
Inflammation was defined in ancient times as ‘rubor, calor, tumor, dolor and 
functio laesa’: redness, heat, swelling, pain and functional impairment. However, 
in the large majority of the cases, this pathologic process starts before the onset 





mediators of tissue functions, among which cytokines and prostanoids. Such a 
release can be triggered by physical, chemical, metabolic, endocrine, infectious as 
well as mechanical events. Nevertheless, many normal functions are regulated by 
the same mediators that in other circumstances give rise to inflammation. Among 
physiological functions ovulation, menstruation, implantation of the product of 
conception, delivery, healing of the placental site and involution of the puerperal 
uterus are included. For instance, as regards the onset of parturition, we have 
shown that receptor ligands for the inflammatory peptide N-formyl-methionyl-
leucyl-phenylalanine (fMLP) are present in amniotic fluid. Their levels do not 
vary during gestation, while they are significantly increased by labour, along with 
the expression of fMLP receptor in amnion tissue, thus indicating a modulation 
of the fMLP system by the events of physiological labour, and/or viceversa [1–3]. 
A detailed knowledge of cytokine and prostanoids involved in the regulation of 
normal pregnancy is needed to better understand the role of inflammatory media-
tors in the pathogenic mechanism of gestational complications.
At this regard it must first be considered that the trophoblast itself, i.e. the 
peripheral part of the product of conception, regulates implantation and placenta-
tion. These are a consequence of membrane ligands and receptors, hormone and 
local factor release by fetal and maternal tissues. There are two kinds of tropho-
blast, villous and extravillous, the first devoted to fetal-maternal nutrients and gas 
exchanges, and the second to adhesion of the placenta to the uterine wall and to 
the modulation of uterine arteries. Indeed, invasion of the uterine spiral arteries by 
extravillous throphoblast occurs, aimed at progressively increasing the perfusion 
of the intervillous space. A derangement of this stuctural and functional process 
leads to different types of complications, including pregnancy loss and maternal 
life-threatening disease.
In the past it was believed that these vascular changes occurred within the first 
half of pregnancy, but today it must be admitted that they last until the moment 
of delivery. From this point of view, pregnancy must be considered an endocrine 
mediated vascular phenomenon, regulated by cytokines mainly derived from the 
extra-villous trophobalst itself [4].
Trophoblast regulation is needed because the rupture of the spiral arterioles, 
with consequent dripping of the maternal blood in which the nutrition villi are 
immersed, in any other tissue except the uterine wall would trigger an inflam-
matory reaction aimed at coagulating the blood to stop hemorrhage. How is it 
possible that this defense mechanism is not activated in physiological pregnancy? 
As it will be explained, the reason is that extravillous trophoblast itself has the task 
of transforming the natural maternal TH-1 inflammatory reaction into an anti-
inflammatory condition of the TH-2 type [5]. The lack of this transformation, in 
fact, leads to pregnancy loss and to other complications, such as premature birth, 
gestosis, fetal growth restriction and related postnatal syndromes [5]. For instance, 
as regards fetal growth, peripheral mononuclear cells stimulated with trophoblast 
antigens [6] as well as with mitogen [7] in pregnant women with fetal growth 
restriction produce higher levels of the pro-inflammatory cytokines IFNγ, TNFα, 
IL-8, IL-12, IL-18, IL-23 and lower anti-inflammatory cytokines IL-4, IL-10, IL-13 
compared with pregnant women with normal fetal growth.
2. The misunderstood concept of ‘maternal tolerance’
Although the scientific literature of the last few decades already contains 
evidence of the leading role of inflammatory cytokines in the mechanisms of 
pregnancy complications, it has not yet been completely understood by mainstream 
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medicine. As a consequence the protective role of glucocorticoids administration is 
neglected or totally ignored.
Moreover, it has not been understood that physiological pregnancy does not 
compromise the general immunity of the maternal organism. At this regard, 
attempts to credit the hypothesis of a reduced maternal immune response are 
frequently made. A theory of maternal-fetal tolerance proposed that a ‘temporary 
state of maternal immunosuppression’ is vital to allow successful implantation and 
development of the product of conception [8, 9].
Subsequently, a tightly regulated balance between inflammatory and tolerogenic 
states during the “immune chronology” of normal pregnancy has been affirmed 
[10–14]. It is claimed that a pro-inflammatory environment predominates during 
early trophoblast invasion and at parturition, while it turns to anti-inflammatory 
during the second and third trimesters to allow fetal growth [15].
All true! What needs to be understood is the real nature of this changes. Indeed, 
it must be clear that it is absolutely wrong to speak of inflammation when a physi-
ological function such as implantation or childbirth is triggered by the same media-
tors that, in pathologic conditions, would cause inflammation. Their derangement 
may trigger inflammation: dosis facit venenum, as Paracelso stated! It is also reported 
that dysregulation of immune cells at the level of maternal decidua is implicated in 
severe complications, including recurrent miscarriage, pre-eclampsia, fetal growth 
restriction, chorioamnionitis, and preterm birth [16–23].
It is therefore very important to understand the nature of the so called ‘maternal 
tolerance’ towards the product of conception, in order to avoid dangerous conclu-
sions. Indeed, it is wrongly claimed that a corollary of this maternal tolerance 
implies an increased susceptibility to infection during pregnancy. In turn, this 
misinterpretation has generated the belief that pregnancy carries a high risk of 
severe flu syndrome which must be prevented by vaccination!
In order to better understand the terms of this matter, it must be briefly recalled 
that normally the changes in maternal immune system occur only at the utero-
placental level, upon the direct action of the trophoblast. The features of these 
changes have nothing in common with the immune response to infections. As for 
the entire maternal organism, the integrity of the immune system is perfectly main-
tained. Both branches of immunity, that is, the humoral and the cellular, are fully 
operational during normal pregnancy. A clear example of the integrity of humoral 
immunity is represented, for instance, by maternal-fetal isoimmunization, i.e. Rh 
disease. In this pathologic condition the maternal immune system activates the 
production of antibodies against Rh positive fetal red blood cells leading to anemia, 
erythroblastosis and possibly to fetal death.
In the lack of a reliable demonstration of an increased incidence of flu and other 
infectious diseases during pregnancy, one may believe that, although active in Rh 
disease, the production of antibodies against viruses and bacteria is hindered. On 
the contrary, in fifty years of my personal clinical experience, I have never detected 
symptoms or signs of a reduced or ineffective maternal immune reactivity against 
infection, nor an increased incidence of infectious diseases in normal pregnancy. 
Moreover, looking at the scientific literature my conviction has been largely con-
firmed. Hundreds of articles including thousand of patients have been recently 
examined as far as flu is concerned. Contrary to the opinion of an increased risk and 
serious complications accredited by World Health Organization (WHO), a signifi-
cantly lower risk of admission to Intensive Care Unit was registered for pregnant 
women. Moreover, no significant difference between pregnant and non-pregnant 
patients was registered, as regards mechanical ventilatory support. Pregnancy did not 
carry a greater likelihood of maternal death or other severe outcomes compared to 
either the general population or non-pregnant women of reproductive age. The only 
Interleukin
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difference between pregnant and non-pregnant was a higher risk of hospitalization in 
the first, that the Authors correctly ascribed to a better care for motherhood [24].
Surprisingly, however, the above data have been interpreted in the opposite 
meaning by others, which also reported a disproportionaly high mortality rate 
in the flu pandemic of 1918 [25]. However, that was before the era of antibiotics, 
anticoagulants and anti-inflammatory drugs (the safety, preventive and therapeutic 
power of which is unfortunately still poorly understood today!).
3. How do infections affect pregnancy?
A further aspect of the matter is the influence of infections on the outcome of 
pregnancy. Indeed, an increased incidence of adverse events following viral infec-
tion would speak in favor of a preventive vaccination aimed at protecting pregnancy 
and the newborn future life.
It has been reported that infectious agents are potentially involved in about 40% 
of spontaneous abortion [26–28]. On the contrary, recent research failed to show an 
increased incidence of several infections in spontaneous abortion. The free mother–
to-child transmission of the three oncogenic viruses, BKPyV, JCPyV and SV40 has 
been shown by detecting DNA sequences and specific IgG antibodies in mothers and 
their offspring in normal pregnancy [29]. The incidence of Human Papilloma Virus 
(HPV) infection is not increased in spontaneous abortion, and the overall prevalence 
of serum anti-HPV16 IgG antibodies was found to be 30% in patients with normal 
pregnancy and 37.5% in those with spontaneous abortion (p > 0.05), thus indicating a 
normal, or even better humoral immunity in the latter [30].
Rubella virus, varicella-zoster, human immunodeficiency virus, adenovirus, 
cytomegalovirus, herpes simplex virus, human parvovirus, Epstein–Barr virus, 
enterovirus and respiratory syncitial virus have all been found in amniotic fluid 
samples, but their mere presence has never been associated with negative human 
pregnancy outcome [31–34]. Based on the above evidences, it should appear that 
the gestational setting of human female immune system is towards a better protec-
tion against infectious diseases compared to non-pregnant.
Interestingly, however, it has been shown that viral experimental infection 
of pregnant mice predisposed to the effects of bacterial endotoxin [35]: it is an 
observation of extraordinary importance to better understand the pathogenesis of 
bacterial infections. Indeed, it explains that the bacteria normally present in their 
saprophytic state can become pathogenic as a consequence of a previously produced 
inflammation.
Accordingly, the onset of human preterm labor is preceded by a systemic fetal 
inflammation, before the appearance of clinical signs of maternal or fetal infection 
[36, 37]. It has been stated that an amniotic concentration of IL6 above 11 ng/ml 
is related to, and defines, the Systemic Fetal Inflammatory Response Syndrome, 
that is followed by premature birth and by utero-placental infection, with all the 
postnatal sequelae, including encephalopathy, enterocolitis and the pulmonary 
hyaline membrane disease.
Of particular importance is to consider what could be the origin of fetal inflam-
mation, in the absence of maternal chronic inflammatory disease, pathogens and 
clinical signs of infection. Indeed, in primates the events leading to premature 
delivery seem to progress from experimental intrauterine infection to pro-inflam-
matory cytokine activation and prostaglandin production, thus triggering myome-
trial contractions [38–40]. In humans, instead, also the mere inflammation of the 
chorio-decidual interface is mentioned as a primum movens producing a cascade of 
cytokines that result in an inflammatory response [41].
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Therefore the question is: when gestational inflammation is not bacterial- or 
viral-induced, where does it come from?
4.  Chromosomal abnormalities and genetic inflammatory 
polymorphisms as a cause of pregnancy inflammation and coagulation
In the absence of chronic maternal inflammatory dysease, the cases with IL-6 
rise preceding infection would speak in favor of a functional inflammation arising 
from the fetus itself. In such cases, based on the above mentioned role of extravil-
lous trophoblast in the control of the local maternal cellular immune response, 
it can be admitted that the shift from TH-1 to TH-2 type of maternal immunity, 
normally resulting from the fetal release of an adequate amount and quality of TH-2 
mediators, did not take place, due to a failure of the trophoblast to correctly balance 
cytokines.
In order to confirm this opinion, it was right to investigate the physiological 
modulators of vascular functions and coagulation, as well as the behavior of cyto-
chines and prostanoids involved in inflammation and smooth muscle contraction, 
in the fetal compartment of pregnancies with fetal aneuploidy. The reason to chose 
aneuploid pregnancies was that very often they end in abortion and, therefore, an 
imbalance of these mediators can be expected.
Accordingly, a significantly increased level of amniotic fluid IL-6, and a decreased 
IL-8 level in the presence of fetal aneuploidy at the 17th week of pregnancy was 
registered, while IL-6 concentration was reduced in the maternal blood [42].
Morover, the comparison between euploid and aneuploid pregnancies with 
respect to maternal serum and amniotic fluid levels of the components of the plas-
minogen system, showed significantly higher serum levels of urokinase plasminogen 
activator and its complexed form with type-1 inhibitor in aneuploidy. In addition, in 
amniotic fluid, tissue plasminogen activator was significantly lower in aneuploidy, 
whereas type-1 inhibitor was significantly higher in the cases with minor chromo-
somal abnormalities. In addition, the complexed form of urokinase plasminogen 
activator with its type-1 inhibitor was 7,53 times higher in aneuploidy [43].
With the aim to shed light on the regulation of the vascular function in pregnan-
cies complicated by fetal chromosomal abnormalities, the potent vasoconstrictor 
peptide endothelin and the proangiogenic nucleoside adenosine were investigated. 
Amniotic fluid levels of endothelin-1 were significantly increased in pregnancies 
with fetal aneuploidy at the 17th gestational week [44]. As regards the adenosine 
transduction cascade, it is disturbed in Trisomy 21. Indeed, compared to euploid, 
reduced adenosine receptors, A [1] and A(2B) expression was revealed in chorionic 
villi and mesenchimal cells [45]. It was suggested that these vascular anomalies may 
lead to fetal growth restriction, malformation and abortion, well known features of 
aneuploid pregnancies.
These results, indicative of an umbalance of cytokines, along with abnormalities 
of vascular function and coagulation in fetal aneuploidies suggest that the related 
gestational complications may arise from the fetus itself. They support the opinion 
that the high incidence of miscarriage observed in chromosomal abnormalities can 
be interpreted as a consequence of inflammation, vascular function impairment 
and coagulation.
However they may also occur in euploid pregnancy, as possible expressions 
of fetal genetic inflammatory polymorphisms. These, indeed, are reported to 
be responsible for harmful inflammatory response in those who possess them. 
Accordingly, it has been demonstrated that maternal polymorphisms in genes IL-10, 
MBL, TNFRSF6 and TGFB1 may influence susceptibility to chorioamnionitis [46]. 
Interleukin
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Furthermore, polymorphisms that increase the magnitude or the duration of the 
inflammatory response are associated with an increased risk of preterm birth, while 
those decreasing the inflammatory response are associated with a lower risk [47]. 
Moreover, an investigation on six cytokine genes associated with inflammation, 
namely IL-1α, IL-1ß, IL-2, IL-6, TNF, and lymphotoxin α, led to the conclusion that 
common genetic variants in proinflammatory cytokine genes do increase the risk 
for spontaneous preterm birth [48].
5. Therapy of cytokine umbalance
5.1 Antibiotics
Once it was established that the major obstetric complications arise from an 
inflammatory process of maternal or fetal origin, the next step was to establish the 
best way to prevent and cure it.
Several clinical studies showed that ajunctive antibiotic therapy aimed at the 
delay of childbirth, even in absence of infection, in cases of so called ‘idiopathic’ 
threatened preterm delivery, was able to significantly prolong pregnancy [49, 50]. 
As some antibiotics influence the intracellular level of calcium [51] and phospholi-
pase A2 [52], a calcium-dependent enzyme involved in the regulation of prostaglan-
din biosynthesis, the question of their possible direct anti-inflammatory action (i.e. 
independent of the antibacterial effect) was raised. Therefore the effect of ampicil-
lin on the amnionic prostaglandin E2 release was tested, showing a significant dose 
dependent inhibitory action of the drug on the prostanoid output. Such a result 
suggested that its use in the therapy of premature labor is authorized even in the 
absence of infection [53]. Subsequently the inhibitory action of beta-lactamines was 
compared with that of other classes of antibiotics. Interestingly, it was found that 
Ceftriaxone and, to a lesser extent, Gentamicin significantly and reversibly inhibit 
both basal and arachidonic acid- or oxytocin-stimulated amnionic prostaglandin E 
release. On the contrary, Tetracycline and Erythromycin do not influence prosta-
glandin E output. The inhibitory effect of ampicillin is potentiated, in an additive 
manner, by Ceftriaxone, reduced by Gentamycin, and eliminated by Tetracycline 
and Erythromycin [54]. A further relevant aspect emerges from the research on the 
novel action of antibiotics mentioned above: the influence of ampicillin on IL-6, 
one of the TH-1 cytokines able to stimulate Prostaglandin E2 release. The effect of 
the drug was tested on amnion-like Wistar Institute Susan Hayflick (WISH) cells 
as well as in amniotic fluid of patients submitted to genetic amniocentesis during 
the 17th week of their singleton physiological pregnancy. At doses ranging from 
10−7 to 10−4 M, ampicillin decreased IL-6 as well as PGE2 release from WISH cells. 
Moreover, IL-6 amniotic fluid levels sampled 4 hours after ampicillin administra-
tion proved significantly and strongly reduced when compared with those sampled 
either before or 12 hours after treatment [55].
The effects of the above antibiotics shed new light on their utility not only in the 
therapy of infection, but also in inflammatory conditions, which often precede it. 
Indeed, contrary to the widespread delay in the use of antibiotics for fear that they 
may favor the appearance of resistant bacterial strains (an event limited to particu-
lar cases, which can be solved by replacing the drug), those antinflammatory effects 
support the indication for the early or even preventive use of beta-lactamines, in 
order to suppress inflammation. Therefore, to this purpose, beta-lactamines can 
represent the first choise, aimed at preventing the infection of the inflammed tis-
sue. It could be argued that there are other steroidal and non-steroidal drugs to fight 
inflammation. It’s true. But inflammation has many little-known aspects, and here 
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one talks about the one that precedes and favors the infection, in which the anti-
inflammatory action of antibiotics would logically seem preferable to that of drugs 
without bactericidal activity.
Based on the above considerations, the preventive use of beta-lactamines in 
invasive prenatal diagnosis was introduced four decedes ago at the obstetrical 
departement of Ferrara University Hospital. Indeed, amnicentesis, cordocentesis 
and chorionic villous biopsy, like any other surgical procedure, produce inflam-
mation in the injured tissues: myometrium, decidua amnio-chorial membranes, 
placenta, obviously resulting in the release of TH1 cytokines and prostaglandins. 
The reason for choosing beta-lactamines is that they are more effective in reducing 
IL-6 and PGE2 release compared to other classes of antibiotics, and the in vitro 
and in vivo evidence already obtained was certainly sufficient to begin with. Later 
on, the first randomized controlled clinical trial showing the efficacy of antibiotic 
administration before amniocentesis in reducing the incidence of abortion and pre-
mature birth was published [56]. Azithromycin was used in this trial, probably due 
to its wide bactericidal effect. However it was subsequently shown that in pregnant 
rats the drug reduces the level of tumor necrosis factor TNF- α and increases that of 
IL-10, two cytokines with inflammatory and anti-inflammatory action, respectively 
[57]. It should be noted that the article suggests the use of azithromycin to prevent 
pregnancy loss ‘infection- or endotoxin-dependent’. However, as it is shown in the 
Fetal Inflammatory Response Syndrome, inflammation may represent the condition 
preceding, and also leading to infection. Considering for instance the possible pres-
ence of predisposing factors to inflammation, like fetal or maternal genetic inflam-
matory polymorphisms, antibiotic use should not be limited to cure infection, but 
is also indicated to prevent and cure the preceding inflammation. It is our clinical 
opinion that the risk of producing resistant bacterial strains is overestimated, and 
therefore in half a century experience our strategy for prevention of pregnancy loss 
largely included preventive use of antibiotics.
5.2 Lactoferrin
Nevertheless, alternative drugs may be used in the protection of pregnancy, 
when an antinflammatory action is indicated without the need of a anti-bacterial 
one. To this purpose we tested Lactoferrin (LF), an iron-binding glycoprotein with 
anti-inflammatory properties, which is normally present in human organism and 
is largely prescribed to cure anemia. We first reported that a vaginal compound 
containing 300 mg of LF, administered 4 hours before genetic amniocentesis, sig-
nificantly decreases amniotic IL-6 concentration [58]. Subsequently we found that 
the same dose of the compound significantly down-regulates 17 pro-inflammatory 
amniotic cytokines among which IL-9, IL-15, IFN-γ, IP-10, TNF-α, IL-1α and MCP-
3, while it up-regulates several among anti-inflammatory [59]. We also evaluated 
the effect of vaginal LF on amniotic fluid PGE2 level and MMP-TIMP system. We 
found that vaginal lactoferrin significantly lowers PGE 2, active MMP-9, and its 
inhibitor TIMP-1. Conversely, active MMP-2 and MMP-2/TIMP-2 molar ratio are 
increased, whilst TIMP-2 remains unchanged [60].
5.3 Glucocorticoids
Once recognized that the majority of relevant pregnancy complications are 
triggered by an inflammatory process, the preventive and curative role of glucocor-
ticoids has been better clarified. The physiologic adrenal gland circadian production 
of glucocorticoids represents the first defense against inflammation, throughout 
the corticosteroid control of the mediators of cellular functions among which IL-1, 
Interleukin
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IL-6, IL-8, Tumor necrosis factor, granulocyte-macrophage colony-stimulating 
factor (G-CSF), monocyte chemotactic protein-1 (MCP-1) [61]. The complex action 
of glucocorticoids (GCs) is exerted also on cellular cytokine receptors, which are 
increased in some cell types, decreased in others [62, 63]. Examples of the regulatory 
actions of GCs are down-regulation of the expression of the cellular receptors that 
recognize a variety of pathogens (Toll-like receptors) [64], as well as suppression of 
pro-inflammatory and up-regulation of anti-inflammatory cytokines. This effect 
has been reported for dexamethasone in primary isolated murine liver cells [65]. 
Glucocorticoid inhibition of the human pro-IL-lβ gene by decreasing DNA binding 
of transactivators to the signal-responsive enhancer has been shown as well [66].
An important example of the complexity of these regulatory processes to be con-
sidered is that the glucocorticoid receptor (GR) can decrease TNF stimukated IL-6 
transcription independently from GCs, as a protective mechanism against excessive 
inflammation [67]. Moreover GCs are reported to induce, rather than to inhibit, the 
secretion of the migration inhibitory factor (MIF) [68], thus counteracting its own 
inhibition of pro-inflammatory cytokine production.
In addition to the intricate network of stimulatory and inhibitory messengers 
and tissue distribution of receptors, the action of the GCs is subordinated to 
the enzyme that transforms cortisol into cortisone, thus inactivating it: 11-beta 
hydroxysteroid Dehydrogenase [69]. It is widely distributed in the uterus and pla-
centa, in immune cells, skeletal muscle and heart, while it is reported to apparently 
lack in the fetal organism up to the advanced stages of its development. What can 
this lack possibly mean? Well, the first logical implication is that normal embryonic 
development does not fear the effect of cortisone up to the advanced stage of its 
maturation.
At this regard, there is one important point to clarify to the benefit of main-
stream obstetrics, and it is the difference between ‘maturation’ and ‘inflammation’. 
The concept of an improvement of fetal lung maturation by betamethasone was 
first expressed fifty years ago, to explain the decreased incidence of ‘Hyaline 
Membrane Disease’ of neonates following the hormone administration to their 
mothers the day before premature birth [70].
At that time the devastating influence of inflammation on pregnancy had 
not been sufficiently explored, and the ‘Fetal Systemic Inflammatory Response 
Syndrome’ had not been described. Therefore it was believed that the hyaline 
membrane disease was caused by prematurity, and the action of betamethasone 
was to induce a sort of pulmonary maturation. But today, the features of fetal 
inflammation leading to Hyaline Membrane Disease, Necrotising Enterocholitis and 
Encephalopathy are well known, and therefore to keep on talking of ‘maturation’ 
instead of inflammation, it is not only an incorrect opinion: it is also misleading. 
Indeed, such a misinterpretation impairs the correct preventive use of GCs through-
out pregnancy. A deep update is therefore needed in order to renew the guidelines 
on a clinical basis rather than a mere statistical one, as usally done.
Further example of the somewhat contradictory reciprocal influence of the 
mediators of inflammation, is that the pro-inflammatory cytokines, IL-1 and 
TNF-α included, up-regulate 11-β-hydroxysteroid-dehydrogenase mRNA in dif-
ferent cell types. Finally, GCs themselves stimulate the enzyme, appearently as an 
attempt to impaire their own anti-inflammatory effect.
Such complex influences are of particular relevance in understanding the nature 
of a balanced protective action against pregnancy loss. They indicate that the 
behavior of GCs in the regulation of inflammatory processes is far more complex 
than our limited knowledge can imagine: once recognized the number and function 
of the involved mediators, it is impossible to establish the precise order of their 
activation. The clinical protective action of glucocorticoids can only be assessed by 
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the ‘ex juvantibus’ criterion: that is, case by case, from the benefit obtained following 
their administration.
6. Other therapies
The COVID pandemic found health systems around the world unprepared. The 
technical-scientific committees of epidemiologists and virologists failed to consider 
therapeutic strategies, limiting the advice only to preventive measures, such as 
face masks, lockdown and quarantena. However, alongside hundreds of thousands 
of dead there have been happy islands where patients have been properly cared. 
Hyperimmune serum transfusions from recovered patients proved effective in 
saving many human lives [71]. Their efficacy depends on a direct neutralization of 
the virus, by preventing its entry into the cell. Attempts have been made to reduce 
the level of IL-6 by administering its antagonist ‘tocilizumab’ [72]. However, to look 
for a single drug capable of balancing the intricate network of stormy cytokines 
is a legitimate but naive hope: lowering the level of just one cytokine while that of 
many others remains high does not make much sense. Therefore the attention of 
researchers should turn to drugs capable of restoring the balance of cytokines as a 
whole, reducing the level of the inflammatory ones and increasing that of the anti-
inflammatory, as happens with cortisone and lactoferrin.
A similar approach recently suggested the use of α-1-antitrypsin (AAT), a serine 
protease inhibitor providing a defense against the digestion of healty tissue by pro-
teolitic enzymes. Interestingly, AAT blood level is very high during inflammation, 
as well as in advanced pregnancy, while its deficiency causes inflammation and viral 
infections. AAT therapy has been appruved for treatment of chronic obstructive 
pulmonary disease [73], and there is no reason not to test it, even as a preventive 
measure, in a serious emergency as that of the current pandemic.
7. Pregnancy and COVID 19 ‘cytokine storm’
During the first few years of my residency, cases of unrecognized ‘pregnancy 
cytokine storm’ were not uncommon. The pathological condition in which they 
occurred, in advanced gestational age, was called ‘gestosis syndrome’. Today it is 
improperly called pre-eclampsia, due to a possible complication (rare, and not the 
worst): tonic–clonic convulsions. More common are the sequelae of vascular pathol-
ogy: abruptio placentae, and disseminated intravascular coagulation. These are the 
consequence of the inflammation triggered by the cytokine unbalance, that, once 
become extreme, is called ‘storm’. In more advanced Obstetric Units, these ominous 
complications virtually disappeared because their premises are identified and taken 
care of before the onset of cytokine stormy release. This represents the rationale 
of low dose betamethasone therapy throughout the entire course of pregnancy for 
preventing pregnancy loss and elated complications [74–77]. Conversely, when 
cytokines trigger intravasal coagulation at the utero-placental level, the fetus dies, 
just as an adult dies from pulmonary vessels coagulation triggered by COVID 19 
cytokine storm. Indeed, both deaths are caused by suffocation, because the placenta 
is the lung through which the fetus breathes.
A virus does not kill by itself: it does so through inflammation and coagulation, 
two perfectly curable pathologies as long as they are treated in time, that is, at their 
first onset. Unfortunately, in the management of COVID-19 pandemic, Health 




Filtering facepiece respirators (FFRs) as well common face masks were core 
of the world health strategy. However, there is little evidence that by wearing a 
medical mask and washing hands provides significant protection against COVID 19 
contagion. To the best of our knowledge, there is no randomized controlled clinical 
trial that demonstrate the efficacy of face masks in preventing the contagion. After 
all, it is logical to observe that the masks are not watertight, and therefore viruses 
can escape around everywhere. The belief of a possible efficacy, derived from the 
123 years old ‘Flugge’s droplets’ account [78], still ignores that the virus remaines 
viable in aerosols over 3 hours [79], and therefore a delayed infection is likely to 
occur even long after a loose interaction with a carrier.
In addition, there are many unresolved questions regarding the spread of this 
disease. The theory of the ‘patient number 1’, in Italy at first identified at Codogno 
(Lombardia), was nullified by the demonstration of the presence of anti-COVID-19 
antibodies in the blood of healthy donors collected before the start of the pandemic. 
This observation suggests not only that the spread of the virus occurs in a silent 
way, but also that the virus is not able by itself to produce a deadly disease. For that 
to happen, concurrent pathologic conditions are required, some of which are well 
known, some others still unknown.
As reported above, the free transmission of viruses through the air, as well 
through other routes is well known, and scientifically confirmed. Obviously, the 
mere presence of viruses does not necessarily imply that the carriers must get sick: 
it is the well known condition of ‘healty carriers’. On the other hand their absence 
does not exclude that the viruses can meet the same subjects in later periods of their 
life. The onset of the disease requires the concurrence of a compromised immune 
response.
In addition to the above considerations on the free and unrele nting circulation 
of all viral particles, COVID-19 included, the Italian experience in the unsuccess-
ful management of the pandemic also speaks against the effectiveness of medical 
masks. In Italy, from North to South and all the way to the islands, everyone was 
forced to wear a mask, but the large majority of deaths were concentrated in four of 
the northern Regions: Piemonte, Lombardia, Veneto and Emilia Romagna. These 
are the most industrialized, rich and polluted Italian regions, which are regarded 
soundest as far the Italian healthcare system is concerned. However, precisely those 
regions reported the highest death rates, compared to all other Italian regions and 
other nations as well. In spite of wearing medical masks, a large number of Italian 
physicians and health workers died, most of which in the above mentioned regions. 
Further to that, at the beginning of the lockdown, a few hundred Italian citizens 
fled from north to south of the country, being accused of spreading the infection 
in the southern regions, but this did not happen at all. A surveillance study per-
formed among healthcare workers at the ‘Infectious Diseases Cotugno Hospital’ in 
Naples, showed a very low prevalence of the COVID-19 infection among health care 
workers: the reason was that healthy subjects scrupulously follow protected and 
obligatory paths, and wear overalls and helmets that completely isolate them from 
the surrounding environment full of viruses [80].
The efficacy of the measures adopted at Cotugno Hospital therefore explains the 
little or no utility of simple masks in preventing the contagion. At the same time, 
Cotugno’s experience demonstrates that concentrating a large number of carriers 
of high viral load in a limited space, without adopting the correct precautions is a 
serious mistake. How to proliferate subjects with a high viral load? Simple: instead 
of treating adequately the early symptoms of illness, leave them at home a few 
weeks with high fever and without effective medical treatment, then hospitalize 
them when the high viral load boosts inflammation up to the level of asphyxia due 
to pulmonary thrombosis.
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8. Concluding remarks
Death from COVID 19 infection reiterates the same pathogenic mechanism of 
fetal and maternal death in pregnancy: it is a matter of inflammation triggered 
by umbalanced cytokines and coagulation in the lung, the same that happens in 
pregnancy, starting at the utero-placental level. In the first the cause is the virus, in 
the second is the fetus itself, as it is explained in the above reported literature.
In both cases, the cause cannot be eliminated.
The cure, instead, exists: it is the same in both conditions and is very effective. 
The rationale for management is not to fight the cause, but to cure the disease, i.e. 
inflammation, and consequent overlapping bacterial infection and thrombosis.
Therapeutic agents include cortison and eventually other non-steroidal drugs 
against inflammation, antibiotics against superimposed bacterial infection and 
heparin against thrombosis. However, it can be stated: no cytokine umbalance = no 
inflammation, no inflammation = no infection = no intravascular coagulation. 
Moreover, it must be stressed that the treatment is all the more effective the earlier 
it is started. The same therapy that can be effective if started at the first onset of 
symptoms, becomes ‘compassionate’ if started when inflammation and thrombosis 
are already in an advanced stage [81, 82].
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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